Analysts have provided the following ratings for Intellia Therapeutics NTLA within the last quarter:
|Bullish||Somewhat Bullish||Indifferent||Somewhat Bearish||Bearish|
These 11 analysts have an average price target of $108.82 versus the current price of Intellia Therapeutics at $36.245, implying upside.
Below is a summary of how these 11 analysts rated Intellia Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock
This current average represents a 6.1% decrease from the previous average price target of $115.89.
Stay up to date on Intellia Therapeutics analyst ratings.
How Are Analyst Ratings Determined?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.